AAAAAA
Results:
1-14
|
Results: 14
Authors:
Zhang, RS
Straus, FH
DeGroot, LJ
Citation: Rs. Zhang et al., Adenoviral-mediated gene therapy for thyroid carcinoma using thymidine kinase controlled by thyroglobulin promoter demonstrates high specificity and low toxicity, THYROID, 11(2), 2001, pp. 115-123
Authors:
DeGroot, LJ
Citation: Lj. Degroot, Treatment of multinodular goiter by surgery, J ENDOC INV, 24(10), 2001, pp. 820-822
Authors:
DeGroot, LJ
Zhang, RS
Citation: Lj. Degroot et Rs. Zhang, Gene therapy for thyroid cancer: Where do we stand?, J CLIN END, 86(7), 2001, pp. 2923-2928
Authors:
Zhang, RS
DeGroot, LJ
Citation: Rs. Zhang et Lj. Degroot, Gene therapy of established medullary thyroid carcinoma with herpes simplex viral thymidine kinase in a rat tumor model: Relationship of bystander effect and antitumor efficacy, THYROID, 10(4), 2000, pp. 313-319
Authors:
Zhang, RS
DeGroot, LJ
Citation: Rs. Zhang et Lj. Degroot, Genetic immunotherapy of established tumours with adenoviral vectors transducing murine interleukin-12 (mIL12) subunits in a rat medullary thyroid carcinoma model, CLIN ENDOCR, 52(6), 2000, pp. 687-694
Authors:
Kouki, T
Sawai, P
Gardine, CA
Fisfalen, ME
Alegre, ML
DeGroot, LJ
Citation: T. Kouki et al., CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease, J IMMUNOL, 165(11), 2000, pp. 6606-6611
Authors:
Sawai, Y
DeGroot, LJ
Citation: Y. Sawai et Lj. Degroot, Binding of human thyrotropin receptor peptides to a Graves' disease-predisposing human leukocyte antigen class II molecule, J CLIN END, 85(3), 2000, pp. 1176-1179
Authors:
Minemura, K
Takeda, T
Minemura, K
Nagasawa, T
Zhang, RS
Leopardi, R
DeGroot, LJ
Citation: K. Minemura et al., Cell-specific induction of sensitivity to ganciclovir in medullary thyroidcarcinoma cells by adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase, ENDOCRINOL, 141(5), 2000, pp. 1814-1822
Authors:
Takeda, T
Suzuki, S
Nagasawa, T
Liu, RT
DeGroot, LJ
Citation: T. Takeda et al., DNA binding affinity of hTR beta 1 mutants as heterodimers with traps fromdifferent tissues, BIOCHIMIE, 81(4), 1999, pp. 297-308
Authors:
DeGroot, LJ
Citation: Lj. Degroot, Dangerous dogmas in medicine: The nonthyroidal illness syndrome - Author'sresponse, J CLIN END, 84(6), 1999, pp. 2262-2263
Authors:
DeGroot, LJ
Citation: Lj. Degroot, Dangerous dogmas in medicine - Author's response, J CLIN END, 84(5), 1999, pp. 1759-1760
Authors:
Haugen, BR
Pacini, F
Reiners, C
Schlumberger, M
Ladenson, PW
Sherman, SI
Cooper, DS
Graham, KE
Braverman, LE
Skarulis, MC
Davies, TF
DeGroot, LJ
Mazzaferri, EL
Daniels, GH
Ross, DS
Luster, M
Samuels, MH
Becker, DV
Maxon, HR
Cavalieri, RR
Spencer, CA
McEllin, K
Weintraub, BD
Ridgway, EC
Citation: Br. Haugen et al., A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer, J CLIN END, 84(11), 1999, pp. 3877-3885
Authors:
Zhang, RS
Straus, FH
DeGroot, LJ
Citation: Rs. Zhang et al., Effective genetic therapy of established medullary thyroid carcinomas withmurine interleukin-2: Dissemination and cytotoxicity studies in a rat tumor model, ENDOCRINOL, 140(5), 1999, pp. 2152-2158
Authors:
Zhang, RS
Baunoch, D
DeGroot, LJ
Citation: Rs. Zhang et al., Genetic immunotherapy for medullary thyroid carcinoma: Destruction of tumors in mice by in vivo delivery of adenoviral vector transducing the murine interleukin-2 gene, THYROID, 8(12), 1998, pp. 1137-1146
Risultati:
1-14
|